With geneType, you can get a better understanding of your risk. Optimize your screening options with your doctor based on your risk of melanoma.
● Understand your risk of melanoma
● A lifetime risk score and a 10-year risk score
● Discussion points around screening recommendations from the USPSTF
Are you doing all you can to reduce your risk of melanoma?
Would you benefit from additional skin-cancer screening?
GeneType can help you have a joint-decision-making discussion with your HCP.
Get a clearer picture of your risk.
Make screening decisions that fit your needs.
Know your risk of melanoma, so you can take action.
If your question is not shown here, please contact us directly.
Register for your geneType test using our portal.
Depending on the test, you may require access to your medical records (ex. lipid panel or breast density results).
Payment will be collected at time of registration.
Your clinical information will be reviewed by our 3rd party telehealth partner, DNA Visit.
If you qualify for testing, a kit will be shipped to your address on file.
If you do not qualify for testing, you will receive a refund.
Complete buccal sample collection as instructed and return in pre-paid envelope.
Do not eat, drink, smoke, vape or chew gum within 30 minutes of collection.
When your results are ready, you will have the chance to speak with your DNA Visit healthcare provider.
All at-risk patients will be required to speak with the provider prior to results-release.
If your question is not shown here, please Contact us directly.
No. At this time geneType is a self-pay test. However, you may use FSA/HSA to pay for the test.
This test is not applicable to adults who have personal history of melanoma or who have already been shown to have a cancer mutation, for example in the CDKN2A gene, or a diagnosis of a genetic syndrome that may be associated with an elevated risk of melanoma.
Cancer is a multifactorial disease and there are many different risk factors. Of these, geneType integrates the most predictive risk factors into the model. Future models may include additional risk factors as the scientific community’s understanding of melanoma continues to evolve.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
Accredited For Compliance With NPAAC Standards And ISO 15189
